Characterization of invasive meningococcal disease case isolates in Atlantic Canada, 2014 to 2020: Spatial-temporal variations of clones and predicted meningococcal B vaccine coverage

Simple item page

Simple item page

Full item details

creativework.keywords - en
clonal types
meningococcal disease
vaccine coverage
dc.contributor.author
Tsang, Raymond S. W.
Law, Dennis K. S.
Zhou, Jianwei
Haldane, David
Garceau, Richard
Zahariadis, George
Mead, Kristen
Alexander, David
dc.date.accessioned
2023-06-02T13:48:27Z
dc.date.available
2023-06-02T13:48:27Z
dc.date.issued
2022-12-16
dc.description.abstract - en
Introduction. Invasive meningococcal disease (IMD) caused by Neisseria meningitidis may show temporal and geographical changes in both the epidemiology and the characteristics of the strains involved. Gap statement. A study that examined invasive N. meningitidis causing IMD in Atlantic Canada from 2009 to 2013 was published in 2014. Data from subsequent years have not been described. Aim. This study examined the molecular epidemiology of IMD in four Atlantic Provinces of Canada as well as potential serogroup B (MenB) vaccine coverage. Methods. Individual IMD case isolates recovered from 2014 to 2020 were analysed for serotype and serosubtype antigens as well as by whole-genome sequencing (WGS) for prediction of potential MenB vaccine coverage. Results. Of the 56 IMD isolates, 42, 8, 5 and 1 were MenB, serogroup Y, serogroup W (MenW) and serogroup C, respectively. Geographical differences in the distribution of MenB clones revealed concentration of sequence type (ST)-269 clonal complex (cc) and ST-60 cc in Newfoundland and Labrador, while ST-41/44 cc (particularly ST-154) was predominantly found in New Brunswick and Nova Scotia. Core genome multi-locus sequence typing (cgMLST) also separated the New Brunswick and Nova Scotia ST-154 isolates into two clusters, with differences in their nhba and penA alleles. Furthermore, cgMLST also separated the ST-269 cc isolates in Atlantic Canada into the ST-1611 and the ST-269/ST-8924 clusters, with the latter showing high similarity to the ST-269 that first emerged in the Province of Quebec. Genetic Meningococcal Antigen Typing System showed that 54.8 % of MenB were predicted to be covered by the MenB vaccine Bexsero, with a further 38.1 % potentially covered by virtue of the presence of genes that encoded factor H-binding protein variant 1 proteins. Meningococcal deduced vaccine antigen reactivity predicted from WGS data showed that 95.3 % of MenB were covered by Trumenba. Four cases of IMD due to MenW ST-11 cc were also identified, with the first case found in 2018. Conclusions. This study provided evidence concerning the dynamics of N. meningitidis strains causing IMD in Atlantic Canada, with both geographical and temporal differences found. MenB vaccine appeared to provide good coverage of MenB IMD, especially towards the predominant strain of ST-154.
dc.identifier.doi
https://doi.org/10.1099/jmm.0.001615
dc.identifier.issn
0022-2615
dc.identifier.uri
https://open-science.canada.ca/handle/123456789/514
dc.language.iso
en
dc.publisher
Microbiology Society
dc.rights - en
Creative Commons Attribution 4.0 International (CC BY 4.0)
dc.rights - fr
Creative Commons Attribution 4.0 International (CC BY 4.0)
dc.rights.uri - en
https://creativecommons.org/licenses/by/4.0/
dc.rights.uri - fr
https://creativecommons.org/licenses/by/4.0/deed.fr
dc.subject - en
Health
dc.subject - fr
Santé
dc.subject.en - en
Health
dc.subject.fr - fr
Santé
dc.title - en
Characterization of invasive meningococcal disease case isolates in Atlantic Canada, 2014 to 2020: Spatial-temporal variations of clones and predicted meningococcal B vaccine coverage
dc.type - en
Article
dc.type - fr
Article
local.article.journalissue
12
local.article.journaltitle
Journal of Medical Microbiology
local.article.journalvolume
71
local.peerreview - en
Yes
local.peerreview - fr
Oui
Download(s)

Original bundle

Now showing 1 - 1 of 1

Thumbnail image

Name: CharacterizationInvasiveMeningococcalDiseaseCaseAtlanticCanada_2014-2020SpatialTempVariationsMeningBVaccine.pdf

Size: 1.21 MB

Format: PDF

Download file

Page details

Date modified: